Jan 29, 2020
Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
Jan 09, 2020
Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones
Jan 08, 2020
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
Dec 20, 2019
Compugen Added to the NASDAQ Biotechnology Index
Nov 11, 2019
Compugen Reports Third Quarter 2019 Results
Nov 06, 2019
Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
Nov 05, 2019
Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
Nov 05, 2019
Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
Nov 04, 2019
Compugen Announces FDA Clearance of IND Application for COM902
Oct 28, 2019
Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019
Oct 02, 2019
Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019
Sep 19, 2019
Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS
Aug 05, 2019
Compugen Reports Second Quarter 2019 Results
Jul 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Jul 02, 2019
Compugen Appoints Eran Perry to Its Board of Directors
Jun 14, 2019
World Cancer Immunotherapy Market Report 2019 - Outcome Potential / Fast Tracking / Funding / Technology Environment / Target Solutions
Jun 03, 2019
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
May 22, 2019
Compugen to Present at the Jefferies 2019 Healthcare Conference
May 20, 2019
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
May 20, 2019
Compugen Reports First Quarter 2019 Results